66.37

1.66% -1.12

Cidara Therapeutics Inc (CDTX)

Overview News Price History Option Chain Financials Discussions Forecast

Cidara Therapeutics Inc stock is traded at $66.37, with a volume of 558.36K. It is down -1.66% in the last 24 hours and up +7.87% over the past month. Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.

Previous Close:

$67.49

Open:

$67.94

24h Volume:

558.36K

Relative Volume:

0.79

Market Cap:

$1.68B

Revenue:

$302.00K

Net Income/Loss:

$-117.10M

P/E Ratio:

-5.9632

EPS:

-11.13

Net Cash Flow:

$-129.13M

1W Performance:

+1.77%

1M Performance:

+7.87%

6M Performance:

+208.12%

1Y Performance:

+410.54%

1-Day Range:

$65.69

$68.00

1-Week Range:

$59.80

$69.36

52-Week Range:

$10.14

$69.36

Cidara Therapeutics Inc Stock (CDTX) Company Profile

Name

Cidara Therapeutics Inc

Sector

Healthcare (1157)

Industry

Biotechnology (645)

Phone

858-752-6170

Address

6310 NANCY RIDGE DRIVE, SAN DIEGO, CA

Employee

Twitter

@CidaraThera

Next Earnings Date

2024-10-31

Latest SEC Filings

CDTX's Discussions on Twitter

Compare CDTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CDTX Cidara Therapeutics Inc	66.37	1.60B	302.00K	-117.10M	-129.13M	-11.13
VRTX Vertex Pharmaceuticals Inc	395.12	99.96B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	589.48	60.83B	14.21B	4.46B	3.56B	39.68
ALNY Alnylam Pharmaceuticals Inc	454.38	59.89B	2.46B	-319.09M	-52.09M	-2.47
ARGX Argen X Se Adr	660.00	40.47B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	313.67	37.96B	3.81B	-644.79M	-669.77M	-6.24

Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-18-25	Resumed	H.C. Wainwright	Buy
Mar-12-25	Initiated	Citizens JMP	Mkt Outperform
Jan-27-25	Resumed	Cantor Fitzgerald	Overweight
Dec-13-24	Initiated	RBC Capital Mkts	Outperform
Nov-08-24	Initiated	Guggenheim	Buy
Aug-14-24	Upgrade	H.C. Wainwright	Neutral → Buy
Dec-03-21	Resumed	H.C. Wainwright	Buy
Sep-22-21	Upgrade	WBB Securities	Buy → Strong Buy
Mar-04-21	Initiated	Aegis Capital	Buy
Sep-04-19	Upgrade	Wedbush	Neutral → Outperform
Jul-26-18	Initiated	Citigroup	Buy
Apr-21-17	Initiated	Raymond James	Strong Buy
Apr-17-17	Reiterated	H.C. Wainwright	Buy
Apr-12-17	Initiated	Ladenburg Thalmann	Buy
Apr-11-17	Resumed	Wedbush	Outperform
Feb-22-17	Reiterated	H.C. Wainwright	Buy
Feb-22-17	Upgrade	WBB Securities	Sell → Hold
Dec-21-16	Resumed	Leerink Partners	Outperform
Dec-19-16	Initiated	H.C. Wainwright	Buy
Sep-23-16	Downgrade	WBB Securities	Hold → Sell
Oct-09-15	Upgrade	WBB Securities	Sell → Hold
May-11-15	Initiated	Jefferies	Buy
May-11-15	Initiated	Leerink Partners	Outperform
May-11-15	Initiated	Needham	Buy
May-11-15	Initiated	Wedbush	Outperform
Apr-23-15	Initiated	WBB Securities	Sell

View All

Cidara Therapeutics Inc Stock (CDTX) Latest News

Aug 20, 2025

Cidara Therapeutics Inc. Breaks Below Key Support LevelJuly 2025 Pullbacks & Momentum Based Trading Ideas - beatles.ru

Aug 20, 2025

Aug 18, 2025

Cidara Therapeutics: Promising Trials Amidst Financial Challenges - MSN

Aug 18, 2025

Aug 16, 2025

Will Cidara Therapeutics Inc. bounce back from current supportGold Moves & Capital Efficiency Focused Strategies - Newser

Aug 16, 2025

Comparing Cidara Therapeutics Inc. in custom built stock radarsPrice Action & Daily Stock Momentum Reports - Newser

Aug 16, 2025

What Fibonacci levels say about Cidara Therapeutics Inc. rebound2025 Volatility Report & Fast Entry and Exit Trade Plans - Newser

Aug 16, 2025

Is Cidara Therapeutics Inc. a candidate for recovery playAnalyst Downgrade & High Conviction Buy Zone Alerts - Newser

Aug 16, 2025

What MACD and RSI say about Cidara Therapeutics Inc.2025 Growth vs Value & Long-Term Growth Stock Strategies - Newser

Aug 16, 2025

What does recent volatility data suggest for Cidara Therapeutics Inc.Index Update & Fast Momentum Entry Tips - Newser

Aug 16, 2025

Is Cidara Therapeutics Inc. trending in predictive chart models2025 Bull vs Bear & Short-Term Trading Alerts - Newser

Aug 16, 2025

Comparing LakeShore Biopharma (NASDAQ:LSB) and Cidara Therapeutics (NASDAQ:CDTX) - Defense World

Aug 16, 2025

Why Cidara Therapeutics Inc. stock attracts strong analyst attentionQuarterly Market Review & Stepwise Trade Execution Plans - Newser

Aug 16, 2025

Aug 15, 2025

Published on: 2025-08-15 18:00:40 - Newser

Aug 15, 2025

Cidara Therapeutics Inc. stock trend outlook and recovery path2025 Technical Overview & Fast Momentum Stock Entry Tips - Newser

Aug 15, 2025

Cidara Therapeutics: A High-Conviction Biotech Play with Clear Path to FDA Phase 3 and Market Disruption - AInvest

Aug 15, 2025

Cidara Therapeutics: Still Big Catalysts Ahead Following Impressive Ph2b Readout (CDTX) - Seeking Alpha

Aug 15, 2025

Fund Update: MORGAN STANLEY added 875,198 shares of CIDARA THERAPEUTICS (CDTX) to their portfolio - Quiver Quantitative

Aug 15, 2025

Analyzing recovery setups for Cidara Therapeutics Inc. investorsEarnings Overview Summary & AI Powered Buy/Sell Recommendations - Newser

Aug 15, 2025

Published on: 2025-08-15 04:34:11 - Newser

Aug 15, 2025

Aug 14, 2025

Will Cidara Therapeutics Inc. stock split in the near future2025 Performance Recap & Risk Managed Trade Strategies - Newser

Aug 14, 2025

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Q2 2025 Earnings Call Transcript - MSN

Aug 14, 2025

Aug 13, 2025

What recovery options are there for Cidara Therapeutics Inc.July 2025 Short Interest & Low Risk High Reward Ideas - Newser

Aug 13, 2025

Cidara (CDTX) Q2 Cash Surges 163% - AOL.com

Aug 13, 2025

Aug 12, 2025

Cidara Therapeutics Inc. Pullback Analyzed — Is It Time to ExitMarket Entry and Exit Point Tips From Traders - beatles.ru

Aug 12, 2025

Aug 10, 2025

JMP Securities Raises Cidara Therapeutics (NASDAQ:CDTX) Price Target to $66.00 - Defense World

Aug 10, 2025

Cidara Therapeutics (NASDAQ:CDTX) Given Buy Rating at Needham & Company LLC - Defense World

Aug 10, 2025

Cidara Therapeutics (NASDAQ:CDTX) Price Target Raised to $74.00 - Defense World

Aug 10, 2025

Aug 09, 2025

A Quick Look at Today's Ratings for Cidara Therapeutics(CDTX.US), With a Forecast Between $66 to $74 - 富途牛牛

Aug 09, 2025

Aug 08, 2025

Cidara Therapeutics 2024 Q2 Earnings Net Loss Widens by 569.5% - AInvest

Aug 08, 2025

What moving averages say about Cidara Therapeutics Inc.Free Smart Trade Plans With Risk Protection - Newser

Aug 08, 2025

Cidara Therapeutics price target raised to $74 from $54 at Needham - TipRanks

Aug 08, 2025

Guggenheim raises Cidara Therapeutics stock price target to $70 on FDA meeting progress - Investing.com Canada

Aug 08, 2025

Cidara Therapeutics Rallies On Promising Flu Drug Progress - Finimize

Aug 08, 2025

Cidara Therapeutics Reports Positive Trial Results and Financial Growth - TipRanks

Aug 08, 2025

Earnings call transcript: Sidera Therapeutics’ Q2 2025 innovation focus - Investing.com

Aug 08, 2025

Cidara Therapeutics: Q2 Earnings Snapshot - Manistee News Advocate

Aug 08, 2025

Cidara Therapeutics stock price target raised to $66 at Citizens JMP - Investing.com Australia

Aug 08, 2025